Inmune Bio’s Promising Pipeline and Strategic Positioning Earns Buy Rating from Analyst

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Inmune Bio (INMB – Research Report), retaining the price target of $30.00.

Jason McCarthy has given his Buy rating due to a combination of factors that highlight Inmune Bio’s promising developments and strategic positioning. The company is on the verge of releasing pivotal Phase 2 data for its XPro treatment in Alzheimer’s disease, expected in mid to late June, which could significantly impact its market position. This treatment is particularly noteworthy as it may offer a unique solution for a subset of Alzheimer’s patients who are not eligible for existing amyloid therapies due to ARIA risks.
Additionally, Inmune Bio is advancing its CORDStrom cell therapy for Recessive Dystrophic Epidermolysis Bullosa, with a Biologics License Application submission anticipated in early 2026. The ongoing INKmune study in metastatic castration-resistant prostate cancer further diversifies its pipeline, with interim data expected throughout 2025. These strategic initiatives, coupled with a solid cash position to support operations into the second half of 2025, underpin McCarthy’s optimistic outlook for the company’s stock.

McCarthy covers the Healthcare sector, focusing on stocks such as Medicus Pharma Ltd, SELLAS Life Sciences Group, and Actinium Pharmaceuticals. According to TipRanks, McCarthy has an average return of -22.2% and a 25.25% success rate on recommended stocks.

In another report released on May 9, Alliance Global Partners also maintained a Buy rating on the stock with a $20.00 price target.